An interventional study of Monopolar transurethral enucleation of the prostate without suprapubic cystostomy and Monopolar transurethral enucleation of the prostate with suprapubic cystostomy in Benign Prostate Hypertrophy(BPH), sponsored by Beni-Suef University. Completed at 1 site in Egypt. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment
Among 11 studies in Prostatic Hyperplasia by Beni-Suef University — 5 open to participants now, 5 under way, none of them phase 3. Prostatic Hyperplasia · Beni-Suef University.
Among the 11 studies in Prostatic Hyperplasia by Beni-Suef University, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 6 with no phase, and was the 5th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →5 of the 11 studies in Prostatic Hyperplasia by Beni-Suef University are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
By country, each count listing its studies:
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 120 across the 11 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beni-Suef University is the lead sponsor of 349 studies on the registry; 123 are open to participants now.
4 of the studies in Prostatic Hyperplasia by Beni-Suef University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07650968Beni-Suef UniversityTamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention | 2027-05 |
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
| NCT07648875Beni-Suef UniversityWater Vapor Thermal Therapy Versus Ejaculation-Preserving HoLEP for Benign Prostatic Hyperplasia | 2027-11 |
| NCT07648888Beni-Suef UniversityWater Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation for Benign Prostatic Hyperplasia | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 11 studies in Prostatic Hyperplasia by Beni-Suef University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
SPC use has previously been evaluated in monopolar transurethral enucleation and resection of the prostate (M-TUERP) compared with bipolar TURP [10]. However, to our knowledge, this is the first randomized controlled trial to compare outcomes of M-TUEP performed with versus without SPC in balanced patient groups. This study evaluates the safety and efficacy of M-TUEP with and without SPC in 160 patients with large prostatic adenomas.
To evaluate whether suprapubic cystostomy (SPC) improves the safety and operative efficiency of monopolar transurethral enucleation of the prostate (M-TUEP) in patients with large benign prostatic hyperplasia (BPH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: Monopolar transurethral enucleation of the prostate without suprapubic cystostomy
Procedure: Monopolar transurethral enucleation of the prostate with suprapubic cystostomy
Monopolar transurethral enucleation of the prostate without suprapubic cystostomy
Monopolar transurethral enucleation of the prostate with suprapubic cystostomy
Operative time
Operative time will be assessed as the total duration of the surgical procedure, measured in minutes from the start of resection to completion of surgery. Shorter operative times indicate greater procedural efficiency.
Time frame: Intraoperative
Resection Efficiency Calculated From Resected Tissue Weight and Operative Time
Resection efficiency will be assessed by dividing the weight of resected prostatic tissue (grams) by operative time (minutes), expressed as grams per minute (g/min). Higher values indicate greater surgical resection efficiency.
Time frame: Intraoperative
International Prostate Symptom Score (IPSS)
The total score ranges from 0 to 35, where higher scores indicate more severe urinary symptoms and worse clinical status.
Time frame: 1, 6, and 12 months
Maximum Urinary Flow Rate Assessed by Uroflowmetry (Qmax)
Maximum urinary flow rate (Qmax) will be assessed using uroflowmetry and reported in milliliters per second (mL/s). Higher values indicate better urinary flow and improved urinary function.
Time frame: 1, 6, and 12 months
Hemoglobin Level Assessed by Laboratory Blood Analysis
Hemoglobin level will be assessed using standard laboratory blood testing and reported in grams per deciliter (g/dL). Changes in hemoglobin levels will be used to evaluate perioperative blood loss.
Time frame: Baseline and immediately after the intervention
Serum Sodium Level Assessed by Laboratory Blood Analysis
Serum sodium level will be assessed using standard laboratory blood testing and reported in milliequivalents per liter (mEq/L) or millimoles per liter (mmol/L). Changes in serum sodium levels will be used to assess fluid and electrolyte balance during the perioperative period.
Time frame: Baseline and immediately after the intervention
Catheterization Time Following Surgery
Catheterization time will be assessed as the duration of postoperative urinary catheter placement, measured in hours or days from catheter insertion to removal. Shorter catheterization times indicate faster postoperative recovery.
Time frame: immediately after the intervention
Length of Hospital Stay Following Surgery
Length of hospital stay will be assessed as the total duration of hospitalization, measured in days from admission or surgery until discharge. Shorter hospital stays indicate improved postoperative recovery and healthcare efficiency.
Time frame: immediately after the intervention
Perioperative Complications Assessed During the Perioperative Period
Perioperative complications will be assessed by clinical evaluation and medical record review during and after surgery. Complications will be categorized according to their type and severity. Higher rates of complications indicate worse surgical safety outcomes.
Time frame: perioperatively
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2022 to primary completion in Oct 2023, 13 months.
Of 153 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's 13 months is below that.
Counting every sponsor, half of 205 studies reached it within 26 months; a quarter within 15 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.